-
公开(公告)号:US12064520B2
公开(公告)日:2024-08-20
申请号:US17694852
申请日:2022-03-15
Inventor: Carlo Giovanni Traverso , Alex G. Abramson , Ester Caffarel Salvador , Niclas Roxhed , Minsoo Khang , Taylor Bensel , Robert S. Langer
IPC: A61K9/48 , A61B5/145 , A61B10/02 , A61B10/06 , A61J3/07 , A61K9/00 , A61K38/28 , A61M5/142 , A61M5/145 , A61M5/158 , A61M5/20 , A61M5/32 , A61M31/00 , A61M37/00 , A61N1/05 , A61N1/32 , A61N1/36
CPC classification number: A61K9/4808 , A61B5/14503 , A61B5/14539 , A61B10/02 , A61J3/07 , A61K9/0002 , A61K9/0012 , A61K9/0021 , A61K9/0065 , A61K9/0092 , A61K9/4866 , A61K38/28 , A61M5/14276 , A61M5/1454 , A61M5/158 , A61M5/2033 , A61M5/329 , A61M5/3295 , A61M31/002 , A61M37/0015 , A61M37/0069 , A61N1/325 , A61N1/36007 , A61B2010/0208 , A61B10/0233 , A61B10/06 , A61M2005/14284 , A61M2005/1581 , A61M2005/1585 , A61M2037/0023 , A61M2037/0053 , A61M2205/0238 , A61M2205/21 , A61M2210/1053 , A61M2210/106 , A61N1/0509
Abstract: Components with relatively high loading of active pharmaceutical ingredients (e.g., drugs), are generally provided. In some embodiments, the component (e.g., a tissue interfacing component) comprises a solid therapeutic agent (e.g., a solid API) and a supporting material (e.g., a binder such as a polymer) such that the solid therapeutic agent is present in the component in an amount of greater than or equal to 10 wt % versus the total weight of the tissue interfacing component. Such tissue-interfacing components may be useful for delivery of API doses e.g., to a subject. Advantageously, in some embodiments, the reduction of volume required to deliver the required API dose as compared to a liquid formulation permits the creation of solid needle delivery systems for a wide variety of drugs in a variety of places/tissues (e.g., tongue, GI mucosal tissue, skin) and/or reduces and/or eliminates the application of an external force in order to inject a drug solution through the small opening in the needle. In some cases, a physiologically relevant dose may be present in a single tissue interfacing component (e.g., having a relatively high API loading).
-
公开(公告)号:US20240150413A1
公开(公告)日:2024-05-09
申请号:US18549951
申请日:2022-03-11
Applicant: Massachusetts Institute of Technology
Inventor: Alexi G. Choueiri , Yong Qian , Bowen Li , Robert S. Langer , Daniel G. Anderson , Edward S. Boyden
IPC: C07K14/005 , A61K38/16 , A61K38/46 , A61P31/14 , C12N9/22
CPC classification number: C07K14/005 , A61K38/162 , A61K38/465 , A61P31/14 , C12N9/22 , C07K2319/735 , C12N2770/20022 , C12N2770/20033
Abstract: In aspects, the invention provides novel compositions and methods for dominant inhibition of viral infection.
-
公开(公告)号:US11850034B2
公开(公告)日:2023-12-26
申请号:US17318040
申请日:2021-05-12
Applicant: Massachusetts Institute of Technology , The Brigham and Women's Hospital, Inc. , The General Hospital Corporation
Inventor: Robert S. Langer , Carlo Giovanni Traverso , Malvika Verma , Feyisope Eweje , Christoph Winfried Johannes Steiger , Junwei Li , Nhi Phan , Hen-Wei Huang , Jacqueline Chu , John Ashraf Fou Salama
CPC classification number: A61B5/073 , A61B5/4845 , A61B2562/02 , A61B2562/162 , A61B2562/164
Abstract: Drug delivery articles, resident articles, and retrieval systems e.g., for gram-level dosing, are generally provided. In some embodiments, the residence articles are configured for transesophageal administration, transesophageal retrieval, and/or gastric retention to/in a subject. In certain embodiments, the residence article includes dimensions configured for transesophageal administration with a gastric resident system. In some cases, the residence article may be configured to control drug release e.g., with zero-order drug kinetics with no potential for burst release for weeks to months. In some embodiments, the residence articles described herein comprise biocompatible materials and/or are safe for gastric retention. In certain embodiments, the residence article includes dimensions configured for transesophageal retrieval. In some cases, the residence articles described herein may comprise relatively large doses of drug (e.g., greater than or equal to 1 gram).
-
公开(公告)号:US11806714B2
公开(公告)日:2023-11-07
申请号:US17075116
申请日:2020-10-20
Applicant: Massachusetts Institute of Technology
Inventor: Armon R. Sharei , Viktor A. Adalsteinsson , Nahyun Cho , Robert S. Langer , J. Christopher Love , Klavs F. Jensen
IPC: B01L3/00 , C12N5/09 , C12N5/078 , G01N15/14 , C12Q1/04 , G01N33/574 , G01N1/30 , G01N15/10 , B82Y30/00 , C12M3/06 , G01N15/00
CPC classification number: B01L3/502761 , C12N5/0634 , C12N5/0693 , C12Q1/04 , G01N15/1459 , G01N15/1484 , G01N33/574 , B01L2200/0652 , B01L2300/08 , B01L2400/0487 , B82Y30/00 , C12M23/16 , G01N1/30 , G01N2015/0065 , G01N2015/1006 , G01N2015/1081
Abstract: Isolating or identifying a cell based on a physical property of said cell can include providing a cell suspension; passing said suspension through a microfluidic channel that includes a constriction; passing the cell suspension through the constriction; and, contacting said cell suspension solution with a compound. The constriction can be sized to preferentially deform a relatively larger cell compared to a relatively smaller cell.
-
公开(公告)号:US20230218535A1
公开(公告)日:2023-07-13
申请号:US18148574
申请日:2022-12-30
Inventor: Robert S. Langer , Carlo Giovanni Traverso , Alex G. Abramson , Michael Williams , Jacob Wainer
CPC classification number: A61K9/4808 , A61M37/0015 , A61M5/158 , A61M5/14276 , A61M5/1454 , A61M37/0069 , A61M2005/1585 , A61M2205/21 , A61M2005/1581 , A61M2205/0238 , A61B10/06 , A61M2210/106 , A61M2037/0023
Abstract: Self-righting articles, such as self-righting capsules for administration to a subject, are generally provided. In some embodiments, the self-righting article may be configured such that the article may orient itself relative to a surface. In some embodiments, the self-righting article may have a particular shape and/or distribution of density (or mass) which, for example, enables the self-righting behavior of the article. In some embodiments, the self-righting article may comprise a tissue interfacing component and/or a pharmaceutical agent. In some cases, upon contact of the tissue with the tissue engaging surface of the article, the self-righting article may be configured to release one or more tissue interfacing components. In some cases, the tissue interfacing component may comprise and/or be associated with the pharmaceutical agent.
-
公开(公告)号:US11684315B2
公开(公告)日:2023-06-27
申请号:US16202647
申请日:2018-11-28
Inventor: Robert S. Langer , Carlo Giovanni Traverso , Yong Lin Kong
CPC classification number: A61B5/6885 , A61B5/0031 , A61B5/073 , A61B5/4238 , A61B5/6861 , A61B5/6871 , A61M31/002 , A61B2560/0443 , A61B2562/0285 , A61B2562/162 , A61M2205/0216 , A61M2205/0272 , A61M2205/3523 , A61M2210/1053
Abstract: Gastric resident electronics, devices, systems, and related methods are generally provided. Some embodiments comprise administering (e.g., orally) an (electronic) resident structure to a subject (e.g., a patient) such that the (electronic) resident structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before exiting said location internal to the subject. In some embodiments, the resident structure is a gastric resident electronic. That is to say, in some embodiments, the resident structure is configured for relatively long gastric residence and comprises an electronic component. In some embodiments, the structures and components described herein may comprise one or more components configured for the delivery of an active substance(s) (e.g., a pharmaceutical agent) to the subject. In some embodiments, the device has a modular design, combining an electronic component(s) with materials configured for controlled and/or tunable degradation/dissolution to determine the time at which (gastric) residence is lost and the device exits the location internal to the subject. For example, in some embodiments, the resident structure comprises an electronic component and one or more additional components associated with the electronic component such that the resident structure is configured to be retained at a location internal to a subject for greater than or equal to 24 hours.
-
公开(公告)号:US20230130084A1
公开(公告)日:2023-04-27
申请号:US17749795
申请日:2022-05-20
Inventor: Arturo J. Vegas , Minglin Ma , Kaitlin M. Bratlie , Daniel G. Anderson , Robert S. Langer
Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers.
-
公开(公告)号:US20230098646A1
公开(公告)日:2023-03-30
申请号:US17956032
申请日:2022-09-29
Inventor: Robert S. Langer , Polina Anikeeva , Carlo Giovanni Traverso , Shriya Srinivasan , Marc-Joseph Antonini
Abstract: Articles and systems configured for treating GI motility disorders are generally provided. In some embodiments, an article comprising one or more electrodes (with both sensing and stimulating capabilities) may be configured to stimulate one or more tissues in the GI tract, electrically and/or chemically, to modulate peristalsis and/or allow neuromodulation. In some embodiments, a system comprises a controller that allows for close-loop operation of the article, e.g., such that the article may stimulate (e.g., via a feedback loop) the one or more organs in the GI tract upon receiving sensed parameters in the GI tract. In some embodiments, an implantation tool comprising a sensor may allow for submucosal or intramuscular implantation of an article. The implantation tool and the article may be useful for, for example, as a general platform for delivery of treating GI motility disorders and/or neuromodulation of the GI tract.
-
公开(公告)号:US11541016B2
公开(公告)日:2023-01-03
申请号:US16899644
申请日:2020-06-12
Inventor: Robert S. Langer , Carlo Giovanni Traverso , Alex G. Abramson , Michael Williams , Jacob Wainer
Abstract: Self-righting articles, such as self-righting capsules for administration to a subject, are generally provided. In some embodiments, the self-righting article may be configured such that the article may orient itself relative to a surface (e.g., a surface of a tissue of a subject). The self-righting articles described herein may comprise one or more tissue engaging surfaces configured to engage (e.g., interface with, inject into, anchor) with a surface (e.g., a surface of a tissue of a subject). In some embodiments, the self-righting article may have a particular shape and/or distribution of density (or mass) which, for example, enables the self-righting behavior of the article. In some embodiments, the self-righting article may comprise a tissue interfacing component and/or a pharmaceutical agent (e.g., for delivery of the active pharmaceutical agent to a location internal of the subject). In some cases, upon contact of the tissue with the tissue engaging surface of the article, the self-righting article may be configured to release one or more tissue interfacing components. In some cases, the tissue interfacing component is associated with a self-actuating component. For example, the self-righting article may comprise a self-actuating component configured, upon exposure to a fluid, to release the tissue interfacing component from the self-righting article. In some cases, the tissue interfacing component may comprise and/or be associated with the pharmaceutical agent (e.g., for delivery to a location internal to a subject).
-
公开(公告)号:US11541015B2
公开(公告)日:2023-01-03
申请号:US16614229
申请日:2018-05-17
Inventor: Carlo Giovanni Traverso , Alex G. Abramson , Ester Caffarel Salvador , Niclas Roxhed , Minsoo Khang , Taylor Bensel , Robert S. Langer
Abstract: Self-righting articles, such as self-righting capsules for administration to a subject, are generally provided. In some embodiments, the self-righting article may be configured such that the article may orient itself relative to a surface (e.g., a surface of a tissue of a subject). The self-righting articles described herein may comprise one or more tissue engaging surfaces configured to engage (e.g., interface with, inject into, anchor) with a surface (e.g., a surface of a tissue of a subject). In some embodiments, the self-righting article may have a particular shape and/or distribution of density (or mass) which, for example, enables the self-righting behavior of the article. In some embodiments, the self-righting article may comprise a tissue interfacing component and/or a pharmaceutical agent (e.g., for delivery of the active pharmaceutical agent to a location internal of the subject). In some cases, upon contact of the tissue with the tissue engaging surface of the article, the self-righting article may be configured to release one or more tissue interfacing components. In some cases, the tissue interfacing component is associated with a self-actuating component. For example, the self-righting article may comprise a self-actuating component configured, upon exposure to a fluid, to release the tissue interfacing component from the self-righting article. In some cases, the tissue interfacing component may comprise and/or be associated with the pharmaceutical agent (e.g., for delivery to a location internal to a subject).
-
-
-
-
-
-
-
-
-